停用阿片类药物评分(SOS)在骨科术后持续处方阿片类药物使用中的验证
这项回顾性队列研究纳入2018年1月1日至2022年3月31日期间接受多种代表性骨科手术的26114例患者,验证SOS评分对术后持续处方阿片类药物使用(连续处方≥90天)的预测效能。低危组(SOS评分<30)持续使用率为1.3%,中危组(30-60)为7.4%,高危组(>60)为20.8%,总体c统计量为0.82。结论认为SOS评分可用于跨亚专科的多种骨科手术后持续阿片类药物使用的验证。
要点
- SOS评分在多种骨科手术后持续阿片类药物使用中验证有效,总体c统计量为0.82。
- 低危组(SOS评分<30)持续使用率为1.3%,中危组(30-60)为7.4%,高危组(>60)为20.8%。
- SOS评分预测效能随时间未见恶化,疫情前c统计量为0.79,疫情期间各波次为0.77至0.80。
核心结论
- SOS评分在跨亚专科的多种骨科手术后持续处方阿片类药物使用中得到验证,总体c统计量为0.82。
- 该工具易于实施,可用于前瞻性识别肌肉骨骼服务线中持续阿片类药物使用风险较高的患者,从而为未来实施上游干预和调整措施以预防阿片类药物滥用和对抗阿片类药物流行提供条件。
研究设计与样本
- 回顾性队列研究,纳入2018年1月1日至2022年3月31日期间接受代表性骨科手术的患者,共26114例,其中女性占51.6%,白人占78.1%,中位年龄63岁。
- 手术类型包括肩袖修复、腰椎间盘切除术、腰椎融合术、全膝关节和全髋关节置换术、踝关节骨折切开复位内固定(ORIF)、桡骨远端骨折ORIF和前交叉韧带重建。
- 通过计算c统计量、受试者工作特征曲线和术后持续处方阿片类药物使用(定义为连续处方阿片类药物≥90天)的观察发生率评估SOS评分效能;敏感性分析比较与COVID-19疫情相关的不同时间段的这些指标。
主要发现
- 低危组(SOS评分<30)持续阿片类药物使用观察发生率为1.3%(95%CI,1.2%至1.5%)。
- 中危组(SOS评分30至60)持续阿片类药物使用观察发生率为7.4%(95%CI,6.9%至8.0%)。
- 高危组(SOS评分>60)持续阿片类药物使用观察发生率为20.8%(95%CI,17.7%至24.2%)。
- 总体组SOS评分效能强,c统计量为0.82;SOS评分效能未见随时间恶化,COVID-19疫情前c统计量为0.79,疫情期间各波次c统计量范围为0.77至0.80。
临床怎么用
- 作者认为该工具易于实施,可用于前瞻性识别肌肉骨骼服务线中持续阿片类药物使用风险较高的患者,从而为未来实施上游干预和调整措施以预防阿片类药物滥用和对抗阿片类药物流行提供条件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Stopping Opioids after Surgery (SOS) score was developed to identify patients at risk for sustained opioid use following surgery. The SOS score has not been specifically validated for patients in a general orthopaedic context. Our primary objective was to validate the SOS score within this context. METHODS: In this retrospective cohort study, we considered a broad array of representative orthopaedic procedures performed between January 1, 2018, and March 31, 2022. These procedures included rotator cuff repair, lumbar discectomy, lumbar fusion, total knee and total hip arthroplasty, open reduction and internal fixation (ORIF) of ankle fracture, ORIF of distal radial fracture, and anterior cruciate ligament reconstruction. The performance of the SOS score was evaluated by calculating the c-statistic, receiver operating characteristic curve, and the observed rates of sustained prescription opioid use (defined as uninterrupted prescriptions of opioids for ≥90 days) following surgery. For our sensitivity analysis, we compared these metrics among various time epochs related to the COVID-19 pandemic. RESULTS: A total of 26,114 patients were included, of whom 51.6% were female and 78.1% were White. The median age was 63 years. The observed prevalence of sustained opioid use was 1.3% (95% confidence interval [CI], 1.2% to 1.5%) in the low-risk group (SOS score of <30), 7.4% (95% CI, 6.9% to 8.0%) in the medium-risk group (SOS score of 30 to 60), and 20.8% (95% CI, 17.7% to 24.2%) in the high-risk group (SOS score of >60). The performance of the SOS score in the overall group was strong, with a c-statistic of 0.82. The performance of the SOS score showed no evidence of worsening over time. The c-statistic was 0.79 before the COVID-19 pandemic and ranged from 0.77 to 0.80 throughout the waves of the pandemic. CONCLUSIONS: We validated the use of the SOS score for sustained prescription opioid use following a diverse array of orthopaedic procedures across subspecialties. This tool is easy to implement for the purpose of prospectively identifying patients in musculoskeletal service lines who are at higher risk for sustained opioid use, thereby enabling the future implementation of upstream interventions and modifications to avert opioid abuse and to combat the opioid epidemic. LEVEL OF EVIDENCE: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Crawford AM, Striano BM, Gong J, et al. Validation of the Stopping Opioids After Surgery (SOS) Score for the Sustained Use of Prescription Opioids Following Orthopaedic Surgery. J Bone Joint Surg Am. 2023. PMID: 37410854. doi:10.2106/JBJS.23.00061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。